These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18811876)

  • 1. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma.
    Lee KS; Park SJ; Kim SR; Min KH; Jin SM; Puri KD; Lee YC
    J Allergy Clin Immunol; 2006 Aug; 118(2):403-9. PubMed ID: 16890765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
    Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
    Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
    Billottet C; Grandage VL; Gale RE; Quattropani A; Rommel C; Vanhaesebroeck B; Khwaja A
    Oncogene; 2006 Oct; 25(50):6648-59. PubMed ID: 16702948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
    Oudit GY; Penninger JM
    Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
    Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
    Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
    Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
    Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
    Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
    Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice.
    Takeda M; Ito W; Tanabe M; Ueki S; Kato H; Kihara J; Tanigai T; Chiba T; Yamaguchi K; Kayaba H; Imai Y; Okuyama K; Ohno I; Sasaki T; Chihara J
    J Allergy Clin Immunol; 2009 Apr; 123(4):805-12. PubMed ID: 19232703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of class II phosphoinositide 3-kinase in cell signalling.
    Falasca M; Maffucci T
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):211-4. PubMed ID: 17371240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do phosphoinositide 3-kinases direct lymphocyte navigation?
    Ward SG
    Trends Immunol; 2004 Feb; 25(2):67-74. PubMed ID: 15102365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.